New Research In Global Clostridium Difficile Infection Treatment Market With Regional Analysis

Clostridium difficile, which produces gram-positive bacterium, is an anaerobic toxin that gets transmitted through fecal-oral route. Clostridium difficile infection occurs during antibiotic treatment or can be caused due to healthcare associated infection with clinical manifestation ranging from asymptomatic infection to watery diarrhea or serious intestinal condition such as colitis and colonic perforation. This infection can be diagnosed by enzyme immunoassays for toxins or Clostridium difficile glutamate dehydrogenase (GDH) and nucleic acid amplification tests for Clostridium difficile toxin genes or endoscopy. Limited types of drugs such as metronidazole, fidoxamycin and vancomycin are only available for the treatment of Clostridium difficile infection. In case of any severe pain or toxic megacolon in abdominal wall, patients undergo surgery for removal of infected portion. High prevalence of this disease and occasional disease outbreaks in the emerging economies are expected to drive growth of Clostridium difficile infection treatment market. However, alternative therapy for broad spectrum antibiotic such as cephalosporins or fluoroquinolone will hinder the growth of Clostridium difficile infection treatment market.

Get The Holistic SAMPLE With Research Methodology:

https://www.coherentmarketinsights.com/insight/request-sample/1492

The Global Clostridium Difficile Infection Treatment Market – Regional Analysis

On the basis of region, the global Clostridium difficile infection treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be a dominant market region over the forecast period due to increasing prevalence of Clostridium difficile infection in this region. Furthermore, European economies are expected to face a decline in Clostridium difficile infection treatment market due to mandatory surveillance, monitoring of antibiotic prescriptions, and reformed compliance with isolation, hand washing, and hygiene protocols. The statistics revealed by Public Health England suggests that Clostridium difficile infection has substantially decreased from 55,498 cases to 13,361 cases between the period of 2007- 2008 and 2013 -2014. Asia pacific is the largest market region due to poor healthcare infrastructure and facilities, and lack of hygiene conditions.

The Global Clostridium Difficile Infection Treatment Market - Competitors

The major players operating in the Clostridium difficile infection treatment market include Merck & Co., Inc., Baxter International Inc., Sanofi S.A., Pfizer limited, Novartis, Astellas Pharma Inc., Eli Lilly and Company, AstraZeneca Plc., Actelion Pharmaceuticals Ltd (Sub. of Johnson & Johnson Services, Inc.), and Mylan N.V.

Get Table Of Content:

https://www.coherentmarketinsights.com/ongoing-insight/toc/1492

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

Visit our news Website:https://www.coherenttimes.org

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging